Ms Mercedes R Colangelo, PA in Framingham, MA - Medicare Physician Assistant

Ms Mercedes R Colangelo, PA is a medicare enrolled "Physician Assistant" physician in Framingham, Massachusetts. Her current practice location is 115 Lincoln St, Framingham, Massachusetts. You can reach out to her office (for appointments etc.) via phone at (508) 383-1104.

Ms Mercedes R Colangelo is licensed to practice in Massachusetts (license number PA2129) and she also participates in the medicare program. She does not accept medicare assignments directly but she may accept medicare through third-party (refer to Reassignment section below) and may also prescribe medicare part D drugs. Her NPI Number is 1144277070.

Contact Information

	Ms Mercedes R Colangelo, PA
	115 Lincoln St, Framingham, MA 01702-6358
	(508) 383-1104
	Not Available

Physician's Profile

Full Name	Ms Mercedes R Colangelo
Gender	Female
Speciality	Physician Assistant
Location	115 Lincoln St, Framingham, Massachusetts
Accepts Medicare Assignments	Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs.

NPI Data:

NPI Number: 1144277070
Provider Enumeration Date: 05/27/2006
Last Update Date: 07/17/2023

Medicare PECOS Information:

PECOS PAC ID: 1254329451
Enrollment ID: I20100617000073

Medical Identifiers

Medical identifiers for Ms Mercedes R Colangelo such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1144277070	NPI	-	NPPES
3981220	Other	AZ	EVERCARE GRP
AW1436	Other	AZ	HEALTHNET GRP
832685	Medicaid	AZ
86C373636	Other	AZ	HUMANA GROUP
453051001	Other	AZ	GROUP HEALTH GRP

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207P00000X	Emergency Medicine	2935 (Arizona)	Secondary
363A00000X	Physician Assistant	PA2129 (Massachusetts)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Ms Mercedes R Colangelo is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Ms Mercedes R Colangelo, PA 115 Lincoln St, Framingham, MA 01702-6358 Ph: (508) 383-1104	Ms Mercedes R Colangelo, PA 115 Lincoln St, Framingham, MA 01702-6358 Ph: (508) 383-1104

News Archive

Potassium salts in plant foods improve bone health

Latest research from the University of Surrey has found that the potassium salts (bicarbonate and citrate) plentiful in fruit and vegetables, play an important part in improving bone health. For the first time, the results also showed that these potassium salts reduce bone resorption, the process by which bone is broken down, therefore increasing their strength.

Researchers urge caution in treating injured young athletes with cell-based therapies

Physicians, parents and coaches should be cautious when considering treating injured young athletes with platelet rich plasma (PRP), stem cells or other types of regenerative medicine, says a nationally recognized sports medicine clinician and researcher at the University of Miami Miller School of Medicine and UHealth Sports Medicine Institute.

The resurgence of gene therapy pioneer

Twenty years ago, scientists and investors were giddy over the promise of gene therapy to cure a host of deadly diseases. But the tragic death of a young man from an experimental treatment in 1999 nearly ended a scientist's career and the entire field.

Blocking gene's activity may control deadly skin cancer without harming normal cells

Researchers at Dana-Farber Cancer Institute and Children's Hospital Boston have discovered that malignant melanoma, the potentially lethal skin cancer, can't grow without a steady supply of a protein that normal cells can do without.

Targeted therapy plus hormone therapy improves survival in premenopausal patients with advanced HR+ breast cancer

Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

Ms Mercedes R Colangelo, PA - Medicare Physician Assistant in Framingham, MA